{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:11:03Z","timestamp":1787015463137,"version":"build-2736575974"},"reference-count":61,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Advances in genetic sequencing technology have enabled identification of the somatic and germline variants that underlie many vascular anomalies. These pathogenic variants often affect one of two signalling pathways: (1) the PI3K (phosphoinositide 3\u2010kinase)\/AKT (protein kinase B)\/mTOR (mammalian target of rapamycin) pathway and (2) the RAS (rat sarcoma)\/RAF (rapidly accelerated fibrosarcoma)\/MEK (mitogen\u2010activated protein kinase)\/ERK (extracellular signal\u2010regulated kinase) pathway. This narrative review aims to synthesize the existing knowledge on the genetic origin of vascular anomalies and the targeted therapeutic approaches. A literature search was conducted using PubMed, Google Scholar and EMBASE, with a key focus on genetic pathways and emerging therapies. mTOR inhibitors have shown efficacy in a range of venous, lymphatic, capillary and syndromic vascular malformations.\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    inhibitors are already commonly used in the treatment of\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    \u2010related overgrowth spectrum (PROS), with current research into new mutant\u2010specific inhibitors aiming to improve selectivity and reduce toxicity.\n                    <jats:italic>AKT<\/jats:italic>\n                    inhibitors are being trialled in Proteus syndrome and PROS.\n                    <jats:italic>MEK<\/jats:italic>\n                    inhibitors have shown efficacy in the treatment of capillary malformations with arteriovenous malformations (CM\u2010AVM) and both\n                    <jats:italic>MEK<\/jats:italic>\n                    and\n                    <jats:italic>BRAF<\/jats:italic>\n                    inhibitors are being investigated for use in extracranial AVMs. Vascular anomalies were previously orphan diseases with minimal effective therapeutic approaches. The discovery of the precise molecular pathways underlying these anomalies has allowed existing drugs to be repurposed for genotype\u2010guided management, enabling a \u2018personalized\u2019 approach to patient care.\n                  <\/jats:p>","DOI":"10.1111\/jdv.70151","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:02:37Z","timestamp":1761663757000},"page":"773-781","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted management of vascular anomalies"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1758-6525","authenticated-orcid":false,"given":"Jessie T.","family":"Lu","sequence":"first","affiliation":[{"name":"School of Clinical Medicine University of New South Wales Medicine and Health  Sydney New South Wales Australia"},{"name":"The Skin Hospital  Sydney New South Wales Australia"},{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-4509","authenticated-orcid":false,"given":"Marra","family":"Aghajani","sequence":"additional","affiliation":[{"name":"The Skin Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-8178","authenticated-orcid":false,"given":"Deshan F.","family":"Sebaratnam","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine University of New South Wales Medicine and Health  Sydney New South Wales Australia"},{"name":"The Skin Hospital  Sydney New South Wales Australia"},{"name":"Department of Dermatology Liverpool Hospital  Liverpool New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000069"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15599"},{"key":"e_1_2_19_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2023.02.004"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2022.02.006"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012199"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.579591"},{"key":"e_1_2_19_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1348096"},{"key":"e_1_2_19_9_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2023.00125"},{"key":"e_1_2_19_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-00943-8"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000102"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2017.02.034"},{"key":"e_1_2_19_13_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318145"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2331"},{"key":"e_1_2_19_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.033"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14624"},{"key":"e_1_2_19_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113387"},{"key":"e_1_2_19_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.02.004"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318142"},{"key":"e_1_2_19_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvsv.2021.01.013"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32023"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23124"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17688"},{"key":"e_1_2_19_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0934-z"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2021.04.071"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOVA.0000000000000101"},{"key":"e_1_2_19_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2025.03.016"},{"key":"e_1_2_19_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.70002"},{"key":"e_1_2_19_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20385"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173095"},{"issue":"7","key":"e_1_2_19_32_1","first-page":"768","article-title":"Alpelisib: a novel therapy for patients with PIK3CA\u2010mutated metastatic breast cancer","volume":"11","author":"Wilhoit T","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03564-z"},{"key":"e_1_2_19_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0217-9"},{"key":"e_1_2_19_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100969"},{"key":"e_1_2_19_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198497"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13597"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0944"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10048-018-0540-1"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115619"},{"key":"e_1_2_19_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2019.01.015"},{"key":"e_1_2_19_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.10.001"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213507"},{"key":"e_1_2_19_44_1","unstructured":"International Society for the Study of Vascular Anomalies (ISSVA).ISSVA classifcation for vascular anomalies. 2018. Available from:https:\/\/www.issva.org\/UserFiles\/file\/ISSVA\u2010Classification\u20102018.pdf(last accessed 27 June 2025)."},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15802"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31605"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026886"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709449"},{"key":"e_1_2_19_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddac169"},{"key":"e_1_2_19_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy218"},{"key":"e_1_2_19_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0479-2"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14912"},{"key":"e_1_2_19_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002990"},{"key":"e_1_2_19_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-022-01986-0"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012324"},{"key":"e_1_2_19_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4653"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172837"},{"key":"e_1_2_19_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/1591019920982810"},{"key":"e_1_2_19_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18046"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98589"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1407683"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02370-2"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:24:02Z","timestamp":1777533842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdv.70151"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70151","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"2025-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}